- Home
- TRVI vs IMTX Comparison
TRVI vs IMTX Comparison
Compare TRVI & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRVI | IMTX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRVI | IMTX |
|---|---|---|
| Price | $12.62 | $9.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $20.59 | $19.25 |
| AVG Volume (30 Days) | ★ 2.4M | 590.7K |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $99,445,031.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.43 | $3.30 |
| 52 Week High | $14.39 | $12.41 |
Technical Indicators
Market Signals| Indicator | TRVI | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 48.62 |
| Support Level | $12.92 | $9.86 |
| Resistance Level | $14.39 | $12.41 |
| Average True Range (ATR) | 0.87 | 0.71 |
| MACD | -0.09 | -0.10 |
| Stochastic Oscillator | 43.71 | 9.40 |
Price Performance
Historical ComparisonAbout TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.